高危子宫内膜癌患者前哨淋巴结评估与全面淋巴结清扫术的结局比较
本研究纳入2014年1月1日至2020年9月1日在本院初治的189例高危子宫内膜癌患者,46例(23.7%)接受前哨淋巴结(SLN)评估,143例(73.7%)接受盆腔±腹主动脉旁淋巴结清扫(LND)。两组3年无进展生存(PFS)率无差异,SLN组未调整总生存(OS)较短,但调整年龄、辅助治疗及手术方式后OS无差异。
要点
- SLN组与LND组3年PFS率分别为71.1%与71.3%(p=0.91),无差异。
- SLN组未调整死亡HR为3.74(95%CI 1.39-10.09;p=0.009),调整后HR 2.90(95%CI 0.94-8.95;p=0.06)未达显著。
- SLN组机器人辅助手术比例高于LND组(p<0.0001)。
核心结论
- 在本队列中,高危子宫内膜癌患者接受SLN评估与全面LND相比,3年PFS无差异。
- SLN组未调整OS较短,但调整年龄、辅助治疗及手术方式后,SLN与LND组OS无差异。
研究设计与样本
- 本研究为在本院开展的队列研究,纳入2014年1月1日至2020年9月1日初治的高危子宫内膜癌患者。
- 共674例诊断为子宫内膜癌,其中189例符合高危标准;46例(23.7%)行SLN评估,143例(73.7%)行LND。
主要发现
- 两组在年龄、组织学、分期、体重指数、肌层浸润、淋巴血管间隙浸润及腹腔冲洗液阳性方面无差异。
- SLN组机器人辅助手术比例高于LND组(p<0.0001)。
- 3年PFS率SLN组71.1%(95%CI 51.3-84.0%)vs LND组71.3%(95%CI 62.0-78.6%)(p=0.91)。
- 复发未调整HR为1.11(95%CI 0.56-2.18;p=0.77),调整后HR为1.04(95%CI 0.47-2.30;p=0.91)。
- 3年OS率SLN组81.1%(95%CI 51.1-93.7%)vs LND组95.1%(95%CI 89.4-97.8%)(p=0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to determine the progression free survival (PFS) and overall survival (OS) among patients with high-risk endometrial cancer (EC) who underwent sentinel lymph node (SLN) mapping and dissection compared to patients who underwent pelvic +/- para-aortic lymphadenectomy (LND). METHODS: Patients with newly diagnosed high-risk EC were identified. Inclusion criteria included patients who underwent primary surgical management from January 1, 2014 to September 1, 2020 at our institution. Patients were categorized into either the SLN or LND group based on their method of planned lymph node assessment. Patients in the SLN group had dye injected followed by successful bilateral lymph node mapping, retrieval, and processing per our institutional protocol. Clinicopathological and follow-up data were extracted from patient's medical records. The t-test or Mann-Whitney test was used to compare continuous variables and Chi-squared or Fisher's exact test were used for categorical variables. Progression-free survival (PFS) was calculated from the date of initial surgery to the date of progression, death, or last follow-up. Overall survival (OS) was calculated from the date of surgical staging to the date of death or last follow-up. Three-year PFS and OS were calculated using the Kaplan-Meier method, and the log-rank test was used to compare cohorts. Multivariable Cox regression models were used to assess the relationship between nodal assessment cohort and OS/PFS while adjusting for age, adjuvant therapy, and surgical approach. A result was considered statistically significant at the p < 0.05 level of significance and all statistical analysis was done using SAS version 9.4 (SAS Institute, Cary, NC). RESULTS: Out of 674 patients diagnosed with EC during the study period, 189 were diagnosed with high-risk EC based on our criteria. Forty-six (23.7%) patients underwent SLN assessment and 143 (73.7%) underwent LND. No difference was observed between the two groups in regards to age, histology, stage, body mass index, tumors myometrial invasion, lymphovascular space invasion, or peritoneal washing positivity. Patients in the SLN group underwent robotic-assisted procedures more frequently than those in the LND group (p < 0.0001). The three-year PFS rate was 71.1% (95% CI 51.3-84.0%) in the SLN group and 71.3% (95% CI 62.0-78.6%) in the LND group (p = 0.91). The unadjusted hazard ratio (HR) for recurrence in the SLN versus LND group was 1.11 (95% CI 0.56-2.18; p = 0.77), and after adjusting for age, adjuvant therapy, and surgical approach, the HR for recurrence was 1.04 (95% CI 0.47-2.30, p = 0.91). The three-year OS rate was 81.1% (95% CI 51.1-93.7%) in the SLN group and 95.1% (95% CI 89.4-97.8%) in the LND group (p = 0.009). Although the unadjusted HR for death was 3.74 in the SLN vs LND group (95% CI 1.39-10.09; p = 0.009), when adjusted for age, adjuvant therapy, and surgical approach, it was no longer significant with a HR of 2.90 (95% CI 0.94-8.95, p = 0.06). CONCLUSIONS: There was no difference in three-year PFS in patients diagnosed with high-risk EC who underwent SLN evaluation compared to those who underwent full LND in our cohort. The SLN group did experience shorter unadjusted OS; however, when adjusting for age, adjuvant therapy and surgical approach, there was no difference OS in patients who underwent SLN compared to LND.
引用
- Holtzman S, Stoffels G, Flint M, et al. Outcomes for patients with high-risk endometrial cancer undergoing sentinel lymph node assessment versus full lymphadenectomy. Gynecol Oncol. 2023. PMID: 37270906. doi:10.1016/j.ygyno.2023.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。